Evidence map›Paper›PMID 37139142›Full record

ArticlePathology oncology research : POR2023

Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients.

Adi Horesh, Rena Pollack, Hovav Nechushtan, Rivka Dresner-Pollak, Tzahi Neuman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Adi HoreshThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Rena PollackThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Hovav NechushtanThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Rivka Dresner-PollakThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Tzahi NeumanThe Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Hadassah Medical Center · ILHebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenHumansImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorRetrospective StudiesThyroid GlandAntineoplastic Agents, ImmunologicalB7-H1 AntigenImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptorimmune checkpoint inhibitorsimmune-related adverse eventsNSCLCPD-L1thyroid

Identifiers

PMID37139142
PMCPMC10149681
OpenAlexW4366224579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.